Literature DB >> 12769347

Retinoic acid induction of CD38 antigen expression on normal and leukemic human myeloid cells: relationship with cell differentiation.

Eugenia Prus1, Eitan Fibach.   

Abstract

Differentiation in the hematopoietic system involves, among other changes, altered expression of antigens, including the CD34 and CD38 surface antigens. In normal hematopoiesis, the most immature stem cells have the CD34 + CD34 - phenotype. In acute myeloid leukemia (AML), although blasts from most patients are CD38 +, some are CD38 - . AML blasts are blocked at early stages of differentiation; in some leukemic cells this block can be overcome by a variety of agents, including retinoids, that induce maturation into macrophages and granulocytes both in vitro and in vivo. Retinoids can also induce CD38 expression. In the present study, we investigated the relationship between induction of CD38 expression and induction of myeloid differentiation by retinoic acid (RA) in normal and leukemic human hematopoietic cells. In the promyelocytic (PML) CD34 - cell lines, HL60 and CB-1, as well as in normal CD34 + CD34 - hematopietic progenitor cells RA induced both CD38 expression as well as morphological and functional myeloid differentiation that resulted in loss of self-renewal. In contrast, in the myeloblastic CD34 + leukemic cell lines, ML-1 and KG-1a, as well as in primary cultures of cells derived from CD34 + -AML (M0 and M1) patients, RA caused an increase in CD38 + that was not associated with significant differentiation. Yet, long exposure of ML-1, but not KG-1, cells to RA resulted in loss of self-renewal. The results suggest that while in normal hematopoietic cells and in PML CD34 - cells induction of CD38 antigen expression by RA results in terminal differentiation along the myeloid lineage, in early myeloblastic leukemic CD34 + cells, induction of CD38 and differentiation are not functionally related. Since, several lines of evidence suggest that the CD38 - cells are the targets of leukemic transformation, transition of these cellsinto CD38 + phenotype by RA or other drugs may have therapeutic effect, either alone or in conjunction with cytotoxic drugs, regardless the ability of the cells to undergo differentiation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12769347     DOI: 10.1080/1042819031000060564

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  8 in total

1.  Retinoic acid suppresses growth of lesions, inhibits peritoneal cytokine secretion, and promotes macrophage differentiation in an immunocompetent mouse model of endometriosis.

Authors:  Friedrich Wieser; Juanjuan Wu; Zhaoju Shen; Robert N Taylor; Neil Sidell
Journal:  Fertil Steril       Date:  2012-03-28       Impact factor: 7.329

Review 2.  Pathogenesis of Endometriosis: Roles of Retinoids and Inflammatory Pathways.

Authors:  Robert N Taylor; Maureen A Kane; Neil Sidell
Journal:  Semin Reprod Med       Date:  2015-07-01       Impact factor: 1.303

3.  Prospective isolation of clonogenic mantle cell lymphoma-initiating cells.

Authors:  Zheng Chen; Paul Ayala; Michael Wang; Luis Fayad; Ruth L Katz; Jorge Romaguera; Nancy Caraway; Sattva S Neelapu; Larry W Kwak; Paul J Simmons; Nami McCarty
Journal:  Stem Cell Res       Date:  2010-08-06       Impact factor: 2.020

4.  Dysregulation of miR-138-5p/RPS6KA1-AP2M1 Is Associated With Poor Prognosis in AML.

Authors:  Dong-Hu Yu; Chen Chen; Xiao-Ping Liu; Jie Yao; Sheng Li; Xiao-Lan Ruan
Journal:  Front Cell Dev Biol       Date:  2021-02-26

Review 5.  Molecular Determinants Underlying the Anti-Cancer Efficacy of CD38 Monoclonal Antibodies in Hematological Malignancies.

Authors:  Nurulhuda Mustafa; Muhamad Irfan Azaman; Giselle G K Ng; Wee Joo Chng
Journal:  Biomolecules       Date:  2022-09-08

6.  Decomposition of gene expression state space trajectories.

Authors:  Jessica C Mar; John Quackenbush
Journal:  PLoS Comput Biol       Date:  2009-12-24       Impact factor: 4.475

7.  ATRA-induced cellular differentiation and CD38 expression inhibits acquisition of BCR-ABL mutations for CML acquired resistance.

Authors:  Zhiqiang Wang; Zheng Liu; Xiwei Wu; Su Chu; Jinhui Wang; Hongfeng Yuan; Mendel Roth; Yate-Ching Yuan; Ravi Bhatia; WenYong Chen
Journal:  PLoS Genet       Date:  2014-06-26       Impact factor: 5.917

8.  Immuno-targeting the multifunctional CD38 using nanobody.

Authors:  Ting Li; Shali Qi; Mandy Unger; Yun Nan Hou; Qi Wen Deng; Jun Liu; Connie M C Lam; Xian Wang Wang; Du Xin; Peng Zhang; Friedrich Koch-Nolte; Quan Hao; Hongmin Zhang; Hon Cheung Lee; Yong Juan Zhao
Journal:  Sci Rep       Date:  2016-06-02       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.